The relationship between immune cells and prostate cancer, and the mediating role of metabolites: a Mendelian randomization study.
Immune cells
Mediator
Mendelian randomization
Metabolites
Prostate cancer
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
07
04
2024
accepted:
28
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Research has demonstrated the significant involvement of immune cells in the development and progression of prostate cancer (PCa). However, the precise causal relationship between immune cells and PCa remains unclear. This study utilized bidirectional Mendelian randomization (MR) analysis to investigate the causal link between immune cells and PCa. Additionally, employed mediation MR design to ascertain the potential mediating role of metabolites in the connection between immune cells and PCa outcomes. Unswitched memory B cell % lymphocyte and CD24 + CD27 + B cell % lymphocyte were positively related to PCa risk, while CD62L - monocyte absolute count and CD62L - monocyte % monocyte were negatively associated with PCa risk. Sensitivity analysis was conducted to validate these results. The mediation MR results indicate that 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) levels may be an independent risk factor for PCa, while the succinate to acetoacetate ratio (SA ratio) was found to be a mediator for the effect of CD62L - monocyte % monocyte on PCa, with a mediation proportion of 16.6% (mediation percentage: 16.6%, 95%CI - 163% - 196%). The research validates the genetic causality between particular immune cells and PCa, and has emphasized the potential intermediary function of SA ratio. These noteworthy discoveries provide fresh perspectives for the clinical management of PCa.
Identifiants
pubmed: 39482407
doi: 10.1038/s41598-024-78085-z
pii: 10.1038/s41598-024-78085-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26217Informations de copyright
© 2024. The Author(s).
Références
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
doi: 10.3322/caac.21492
pubmed: 30207593
Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10(2), 63–89 (2019).
doi: 10.14740/wjon1191
pubmed: 31068988
pmcid: 6497009
Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers https://doi.org/10.1038/s41572-020-00243-0 (2021).
doi: 10.1038/s41572-020-00243-0
pubmed: 33542230
Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77(1), 38–52 (2020).
doi: 10.1016/j.eururo.2019.08.005
pubmed: 31493960
Zi, H. et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Milit. Med. Res. https://doi.org/10.1186/s40779-021-00354-z (2021).
doi: 10.1186/s40779-021-00354-z
Messex, J. K. & Liou, G.-Y. Impact of immune cells in the tumor microenvironment of prostate cancer metastasis. Life 13(2), 333 (2023).
doi: 10.3390/life13020333
pubmed: 36836690
pmcid: 9967893
Catamo, E., Zupin, L., Crovella, S., Celsi, F. & Segat, L. Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Hum. Immunol. 75(12), 1225–1231 (2014).
doi: 10.1016/j.humimm.2014.09.019
pubmed: 25318079
Fisher, J. P. H., Heuijerjans, J., Yan, M., Gustafsson, K. & Anderson, J. γδ T cells for cancer immunotherapy. OncoImmunology 3(1), e27572 (2014).
doi: 10.4161/onci.27572
pubmed: 24734216
pmcid: 3984269
Grigor, E. J. M. et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: A systematic review and meta-analysis. Transfusion Med. .Rev. 33(2), 98–110 (2019).
doi: 10.1016/j.tmrv.2019.01.005
Saleem, S. et al. Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review. Ann. Med. Surg. 85(8), 4005–4014 (2023).
doi: 10.1097/MS9.0000000000001070
Kelly, R. S., Vander Heiden, M. G., Giovannucci, E. & Mucci, L. A. Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence. Cancer Epidemiol. Biomark. Prev. 25(6), 887–906 (2016).
doi: 10.1158/1055-9965.EPI-15-1223
Burgess, S. et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 4, 186 (2023).
doi: 10.12688/wellcomeopenres.15555.3
pubmed: 32760811
pmcid: 7384151
Sanderson, E. et al. Mendelian randomization. Nat. Rev. Methods Primers https://doi.org/10.1038/s43586-021-00092-5 (2022).
doi: 10.1038/s43586-021-00092-5
pubmed: 37325194
pmcid: 7614635
Orrù, V. et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat. Genet. 52(10), 1036–1045 (2020).
doi: 10.1038/s41588-020-0684-4
pubmed: 32929287
pmcid: 8517961
Sidore, C. et al. Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. Nat. Genet. 47(11), 1272–1281 (2015).
doi: 10.1038/ng.3368
pubmed: 26366554
pmcid: 4627508
Cao, R.-R. et al. The immune factors have complex causal regulation effects on bone mineral density. Front. Immunol. https://doi.org/10.3389/fimmu.2022.959417 (2022).
doi: 10.3389/fimmu.2022.959417
pubmed: 36936475
pmcid: 9822570
Chen, Y. et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat. Genet. 55(1), 44–53 (2023).
doi: 10.1038/s41588-022-01270-1
pubmed: 36635386
pmcid: 7614162
Pierce, B. L., Ahsan, H. & Vanderweele, T. J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int. J. Epidemiol. 40(3), 740–752 (2011).
doi: 10.1093/ije/dyq151
pubmed: 20813862
Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat. Med. 36(11), 1783–1802 (2017).
doi: 10.1002/sim.7221
pubmed: 28114746
pmcid: 5434863
Carter, A. R. et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur. J. Epidemiol. 36(5), 465–478 (2021).
doi: 10.1007/s10654-021-00757-1
pubmed: 33961203
pmcid: 8159796
Seifert, M. & Küppers, R. Human memory B cells. Leukemia 30(12), 2283–2292 (2016).
doi: 10.1038/leu.2016.226
pubmed: 27499139
Carril-Ajuria, L. et al. Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. J. Immunother. Cancer 10(5), e004885 (2022).
doi: 10.1136/jitc-2022-004885
pubmed: 35640928
pmcid: 9157347
Murakami, Y. et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci. Rep. 9(1), 13083 (2019).
doi: 10.1038/s41598-019-49581-4
pubmed: 31511630
pmcid: 6739478
Li, W. et al. Reduction in peripheral CD19+CD24hCD27+ B cell frequency predicts favourable clinical course in XELOX-treated patients with advanced gastric cancer. Cell. Physiol. Biochem. 41(5), 2045–2052 (2017).
doi: 10.1159/000475435
pubmed: 28419993
Yang, J. et al. Low percentage of CD24hiCD27(+)CD19(+) B cells decelerates gastric cancer progression in XELOX-treated patients. Int. Immunopharmacol. 26(2), 322–327 (2015).
doi: 10.1016/j.intimp.2015.04.011
pubmed: 25899086
Ngai, H. et al. LEF1 drives a central memory program and supports antitumor activity of natural killer T cells. Cancer Immunol. Res. 11(2), 171–183 (2023).
doi: 10.1158/2326-6066.CIR-22-0333
pubmed: 36484736
pmcid: 9898189
Yang, C. K. et al. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma. PLoS One 18(1), e0280023 (2023).
doi: 10.1371/journal.pone.0280023
pubmed: 36598909
pmcid: 9812323
Liu, C. et al. The potential predictive biomarkers for advanced hepatocellular carcinoma treated with anti-angiogenic drugs in combination with PD-1 antibody. Front. Immunol. 13, 930096 (2022).
doi: 10.3389/fimmu.2022.930096
pubmed: 35874743
pmcid: 9301374
Munoz, L. E. et al. Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. J. Immunother. Cancer 9(11), e002614 (2021).
doi: 10.1136/jitc-2021-002614
pubmed: 34815353
pmcid: 8611422
Kruglov, O. et al. The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. Cancer Immunol. Immunother. 71(4), 919–932 (2022).
doi: 10.1007/s00262-021-03051-x
pubmed: 34519839
Andrejeva, G. & Rathmell, J. C. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 26(1), 49–70 (2017).
doi: 10.1016/j.cmet.2017.06.004
pubmed: 28683294
pmcid: 5555084
Ma, E. H. et al. Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8(+) T cells. Immunity 51(5), 856-870e855 (2019).
doi: 10.1016/j.immuni.2019.09.003
pubmed: 31747582
Kim, J. & DeBerardinis, R. J. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 30(3), 434–446 (2019).
doi: 10.1016/j.cmet.2019.08.013
pubmed: 31484055
pmcid: 6730674
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021).
doi: 10.3322/caac.21654
pubmed: 33433946
Chen, Z., Li, Z., Li, H. & Jiang, Y. Metabolomics: a promising diagnostic and therapeutic implement for breast cancer. Onco Targets Ther. https://doi.org/10.2147/OTT.S215628 (2019).
doi: 10.2147/OTT.S215628
pubmed: 32099386
pmcid: 6997418
Zhang, Z. et al. Investigating the impact of human blood metabolites on the Sepsis development and progression: a study utilizing two-sample Mendelian randomization. Front. Med. (Lausanne) https://doi.org/10.3389/fmed.2023.1310391 (2023).
doi: 10.3389/fmed.2023.1310391
pubmed: 38528958
pmcid: 10751827
Brustad, N. et al. Diet-associated vertically transferred metabolites and risk of asthma, allergy, eczema, and infections in early childhood. Pediatr. Allergy Immunol. 34(2), e13917 (2023).
doi: 10.1111/pai.13917
pubmed: 36825739
Miao, Z. et al. Furan fatty acid metabolite CMPF is associated with lower risk of type 2 diabetes, but not chronic kidney disease: a longitudinal population-based cohort study. Am. J. Clin. Nutr. 118(3), 637–645 (2023).
doi: 10.1016/j.ajcnut.2023.07.016
pubmed: 37482300
Ottosson, F. et al. The inverse association between a fish consumption biomarker and gingival inflammation and periodontitis: A population-based study. J. Clin. Periodontol. 49(4), 353–361 (2022).
doi: 10.1111/jcpe.13602
pubmed: 35132662
pmcid: 9303516
Palviainen, M. et al. Cancer alters the metabolic fingerprint of extracellular vesicles. Cancers (Basel) 12(11), 3292 (2020).
doi: 10.3390/cancers12113292
pubmed: 33172086
Tessem, M. B. et al. A balanced tissue composition reveals new metabolic and gene expression markers in prostate cancer. PLoS One 11(4), e0153727 (2016).
doi: 10.1371/journal.pone.0153727
pubmed: 27100877
pmcid: 4839647
Weber, A. et al. Succinate accumulation is associated with a shift of mitochondrial respiratory control and HIF-1alpha upregulation in PTEN negative prostate cancer cells. Int. J. Mol. Sci. 19(7), 2129 (2018).
doi: 10.3390/ijms19072129
pubmed: 30037119
pmcid: 6073160
Zhang, A. et al. Enhanced succinate oxidation with mitochondrial complex II reactive oxygen species generation in human prostate cancer. Int. J. Mol. Sci. 23(20), 12168 (2022).
doi: 10.3390/ijms232012168
pubmed: 36293021
pmcid: 9603078
Sant’Anna-Silva, A. C. B. et al. Succinate anaplerosis has an onco-driving potential in prostate Cancer Cells. Cancers (Basel) 13(7), 1727 (2021).
doi: 10.3390/cancers13071727
pubmed: 33917317
Leung, K. Acetoacetate. In Molecular Imaging and Contrast Agent Database (MICAD) (National Center for Biotechnology Information (US), 2004–2013).
Authier, S. et al. [11C] acetoacetate utilization by breast and prostate tumors: a PET and biodistribution study in mice. Mol. Imaging Biol. 10(4), 217–223 (2008).
doi: 10.1007/s11307-008-0143-6
pubmed: 18454299